首頁 > 市場調查報告書 > 製藥

呼吸器

市場調查報告書

商品編碼

2003548

全球氣喘治療市場：按給藥途徑、藥物、應用、組織類型和地區分類－市場規模、產業動態、機會分析和預測（2026-2035 年）

Global Asthma Drugs Market: By Mode of Administration, By Medication, Application, Organization Type, Region - Market Size, Industry Dynamics, Opportunity Analysis and Forecast for 2026-2035

出版日期: 2026年02月11日 | 出版商:

Astute Analytica | 英文 260 Pages | 商品交期: 最快1-2個工作天內

價格

簡介目錄

全球氣喘治療市場正經歷重大轉型，從依賴大眾市場吸入藥物轉向以高附加價值標靶生物製藥為重點。這項轉變反映了個人化醫療和氣喘治療領域進步的更廣泛趨勢，治療方法正日益針對特定患者亞型和潛在疾病機制進行最佳化。 2025年，市場規模預計約為265.2億美元，展現了氣喘治療產業的龐大規模。預計該市場將穩定成長，到2035年將達到約411.8億美元。這一成長意味著2026年至2035年預測期內的複合年成長率（CAGR）為4.50%，顯示市場將持續穩定成長。

推動這一預期成長的關鍵因素有幾個。首先，包括氣喘在內的慢性發炎相關呼吸道疾病在全球範圍內的盛行率不斷上升，持續增加對有效治療方法的需求。人口老化和都市化進程加快，導致人們更頻繁地接觸污染和過敏原等環境因素，加劇了患者數量的成長。其次，生物製藥的引入正在迅速推進。這些先進治療方法針對氣喘中涉及的特定發炎通路，能夠改善中重度氣喘患者的治療效果，尤其對於無法透過傳統吸入藥物有效控制症狀的患者。

顯著的市場趨勢

氣喘治療市場競爭異常激烈，主要受大型製藥企業策略性產品系列和標靶生物製藥不斷湧現的影響。Astra ZenecaGlaxoSmithKline Plc（GSK）和賽諾菲（與再生元合作）等主要企業，以及梯瓦和貝翠絲等強大的學名藥生產商，共同主導著市場。這些公司憑藉其強大的研發能力，不斷創新並拓展產品線，力求在滿足氣喘患者不斷變化的需求的同時，維持並提升市場佔有率。

這些製藥巨頭的重點之一是開發和商業化結合支氣管擴張劑和皮質類固醇的聯合治療。這種方法簡化了患者的治療方法，減少了所需的吸入器和藥物數量，從而提高了患者的用藥依從性，並改善了疾病的整體控制。透過提供固定劑量組合藥物，這些公司提供了一種更方便有效的選擇，可以同時解決支氣管收縮和氣道發炎問題，這對於控制氣喘症狀和預防氣喘急性發作至關重要。

除了這些聯合治療外，目前也非常重視開發針對氣喘相關特定發炎路徑的新型生物製藥。這些生物製藥代表著一個快速成長的市場領域，為對傳統治療方法反應不佳的中重度氣喘患者提供了個人化的治療選擇。葛蘭素史克（GSK）的長效生物製藥製劑Exdensur於2025年12月獲得FDA核准，這是一個值得關注的創新案例。 Exdensur旨在持續控制氣喘症狀，這也標誌著葛蘭素史克在監管領域取得了一年的成功。

主要成長促進因素

在亞太地區，氣喘盛行率激增，主要原因是污染加劇和環境因素，這顯著推動了市場成長。與氣喘盛行率相對穩定的西方國家不同，亞太地區因污染引發的氣喘急性發作病例顯著增加，其中包括一種稱為「雷暴氣喘」的現象。這種疾病是指特定天氣模式與高濃度花粉和污染結合，引發突發性嚴重氣喘發作，常常對醫療系統造成巨大壓力。此類事件發生頻率的增加凸顯了該地區居民面臨的日益嚴峻的呼吸系統挑戰。

新成長機會的趨勢

兒童生物製藥的拓展正成為氣喘治療市場的重要成長機會。傳統上，生物製藥（針對氣喘特定路徑的先進藥物）主要核准用於成人患者和年齡較大的青少年。然而，美國食品藥物管理局（FDA）和歐洲藥品管理局（EMA）等監管機構正逐步降低這些治療方法的核准年齡。例如，領先的生物製藥Dupixent（度普利尤單抗）最近核准用於6歲及以上兒童。

最佳化障礙

由於兩種重磅複方製劑－信必可（Symbicort）和舒利迭（Advair）的學名藥一般化，氣喘藥物市場正面臨潛在的成長挑戰。這些藥物結合了皮質類固醇和長效BETA2受體激動劑，多年來一直是氣喘治療的基石，為製藥公司帶來了豐厚的利潤。然而，已通過核准的活性成分佈地Budesonide/Budesonide的學名藥藥獲批上市後，市場供應日益飽和，價格競爭也愈演愈烈。學名藥的湧入不可避免地對品牌藥的銷售造成壓力，侵蝕市場佔有率，並降低整體盈利。

產業價值鏈分析
- 原料供應商（原料藥、添加物）
- 製藥公司（原廠藥廠和學名藥企業）
- 契約製造組織（CMO）
- 經銷商和批發商
- 藥房（零售和醫院）
- 醫療服務提供者（醫院、診所）
- 最終使用者（患者）
產業展望
- 全球氣喘盛行率上升
- 空氣污染加劇和環境因素增多
- 生物製藥和標靶治療的應用日益廣泛
- 政府在呼吸系統疾病管理所做的努力
- 藥物輸送系統（吸入器、霧化器）的進步
- 醫療費用增加
- 提高意識和早期診斷
- 學名藥市場的擴張
PESTLE分析
波特五力分析
- 供應商的議價能力
- 買方的議價能力
- 替代品的威脅
- 新進入者的威脅
- 競爭強度
市場動態和趨勢
- 成長促進因素
- 抑制因子
- 機會
- 主要趨勢
市場成長及前景
- 市場收入估算與預測（2020-2035 年）
- 氣喘藥物價格趨勢分析

第4章：競爭對手儀錶板

市場集中度
企業市場占有率分析（以金額為準，%），2025 年
競爭對手分析與基準測試
Start-Ups生態系分析
併購和資金籌措趨勢

第5章：全球氣喘治療市場分析

關鍵見解
市場規模及預測（2020-2035）
- 透過行政途徑
- 藥物
- 透過使用
- 按組織類型
- 按地區

第6章：北美氣喘治療市場分析

第7章：歐洲氣喘治療市場分析

第8章：亞太地區氣喘治療市場分析

第9章：中東和非洲氣喘治療藥物市場分析

第10章：南美洲氣喘治療市場分析

第11章：公司簡介

AbbVie Inc.
Amgen Inc.
AstraZeneca
Boehringer Ingelheim Intl. GmbH
Chiesi Farmaceutici SpA
Cipla Ltd
Covis Pharma GmbH
F. Hoffmann-La Roche Ltd
GlaxoSmithKline plc
Lupin Ltd
Merck &Co., Inc.
Novartis AG
Orion Corporation
Pfizer Inc.
Regeneron Pharmaceuticals Inc.
Sanofi
Sumitomo Dainippon Pharma Co., Ltd
Takeda Pharmaceutical Co. Ltd
Teva Pharmaceutical Industries Ltd
Viatris Inc.（Mylan）
其他有潛力的企業

第12章附錄

簡介目錄

Product Code: AA02261710

The global asthma drugs market is undergoing a significant transformation, moving away from relying primarily on high-volume inhaler sales toward a greater emphasis on high-value targeted biologics. This shift reflects broader trends in personalized medicine and advancements in asthma treatment, where therapies are increasingly tailored to specific patient subtypes and underlying disease mechanisms. In 2025, the market was valued at approximately USD 26.52 billion, demonstrating the substantial scale of the asthma treatment landscape. Looking ahead, the market is projected to expand robustly, reaching an estimated valuation of USD 41.18 billion by 2035. This growth corresponds to a compound annual growth rate (CAGR) of 4.50% over the forecast period from 2026 to 2035, signaling steady and sustained market expansion.

Several key factors are driving this anticipated growth. Firstly, the rising global prevalence of chronic inflammation-related respiratory conditions, including asthma, continues to increase the demand for effective treatments. As populations age and urbanization intensifies, exposure to environmental triggers such as pollution and allergens is becoming more common, contributing to a growing patient base. Secondly, the adoption of biologics is accelerating rapidly. These advanced therapies target specific inflammatory pathways involved in asthma, offering improved outcomes for patients with moderate to severe disease who are inadequately controlled by traditional inhalers.

Noteworthy Market Developments

The asthma drugs market is highly competitive and significantly shaped by the strategic portfolios of major pharmaceutical companies, as well as the continuous introduction of new, targeted biologic therapies. Leading players such as AstraZeneca, GlaxoSmithKline (GSK), Sanofi in partnership with Regeneron, and prominent generics manufacturers like Teva and Viatris dominate the landscape. These companies leverage their extensive research and development capabilities to innovate and expand their product offerings, aiming to meet the evolving needs of asthma patients while maintaining or growing their market share.

A key focus among these pharmaceutical giants is the development and marketing of combination therapies that integrate bronchodilators with corticosteroids. This approach simplifies treatment regimens for patients by reducing the number of inhalers or medications required, improving adherence, and overall disease management. By offering fixed-dose combinations, companies provide more convenient and effective options that address both bronchoconstriction and airway inflammation simultaneously, which is crucial for controlling asthma symptoms and preventing exacerbations.

Alongside these combination therapies, there is a strong emphasis on the creation of novel biologics that target specific inflammatory pathways involved in asthma. These biologic drugs represent a growing segment within the market, offering personalized treatment options for patients with moderate to severe asthma who do not respond adequately to conventional therapies. A notable example of this innovation occurred in December 2025, when GSK capped off a year of regulatory successes by securing FDA approval for Exdensur, a long-acting biologic designed to provide sustained control of asthma symptoms.

Core Growth Drivers

The Asia-Pacific (APAC) region is experiencing a notable surge in asthma prevalence, driven largely by escalating pollution levels and environmental factors, which are significantly fueling market growth. Unlike Western countries, where asthma prevalence has largely stabilized, APAC is witnessing an alarming increase in cases related to pollution-triggered exacerbations, including a phenomenon known as "Thunderstorm Asthma." This condition occurs when specific weather patterns, combined with high pollen and pollution levels, trigger sudden and severe asthma attacks, often overwhelming healthcare systems. The rising frequency of such events underscores the growing respiratory health challenges faced by populations in this region.

Emerging Opportunity Trends

Pediatric biologic expansion is emerging as a significant growth opportunity within the asthma drugs market. Traditionally, biologic therapies-advanced medications designed to target specific pathways involved in asthma-have been predominantly approved for adult patients or older adolescents. However, regulatory agencies such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) are progressively lowering the approved age thresholds for these treatments. For example, Dupixent (dupilumab), a leading biologic, has recently been approved for use in children aged six and older.

Barriers to Optimization

The asthma drugs market faces potential challenges to its growth due to the generic erosion of two blockbuster combination therapies: Symbicort and Advair. These medications, which combine corticosteroids and long-acting beta-agonists, have long been mainstays in asthma management and have generated substantial revenue for pharmaceutical companies. However, the increasing availability of authorized generics for Budesonide/Formoterol, the active ingredients in Symbicort, is saturating the market and intensifying price competition. This influx of generics inevitably puts pressure on the sales of branded products, eroding their market share and reducing overall profitability.

Detailed Market Segmentation

Based on Mode of Administration, the inhalers segment commanded the highest revenue share in the asthma drugs market, establishing the inhaled route as the preferred mode of administration. This dominance extends beyond the clinical advantages of inhaled therapies, which have long been recognized for delivering medication directly to the lungs with rapid onset and targeted effect. Instead, the leading position of inhalers is now structurally reinforced by what industry experts refer to as the "Device Fortress."

Based on Medication, the quick relief medications segment, primarily composed of short-acting beta-agonists (SABAs), held the largest share of the asthma drugs market. This dominance is not due to these medications being considered the clinical gold standard for asthma management, but rather because they are uniquely "climate-elastic" within the broader respiratory drug portfolio.

Based on Organization Type, the public segment is expected to hold the largest share of the asthma drugs market, underscoring the significant role played by government and publicly funded healthcare organizations in managing asthma treatment. This dominance is closely linked to the phenomenon known as "adverse selection" within insurance markets, where individuals with more severe and uncontrolled asthma disproportionately belong to lower-income groups and elderly populations.

Based on Application, the adult segment emerged as the largest market share holder within the asthma drugs market, reflecting its dominant role in this therapeutic area. This prominence is largely due to the adult population being the primary demographic capable of benefiting from and monetizing advancements in precision medicine. Precision medicine, which tailors treatment based on individual patient characteristics and biomarkers, has gained significant traction in adult asthma management, leading to more effective and targeted therapies.

Segment Breakdown

By Medication

Quick Relief Medications
Long-term Control Medications
Others

By Mode of Administration

Tablets and Capsules
Liquids
Inhalers
Injections

By Organization Type

Public
Private

By Application

Pediatric
Adults
Adolescent

By Region

North America
Europe
Asia Pacific
Middle East and Africa
South America

Geography Breakdown

North America is poised to maintain its leadership position in the global asthma drugs market, commanding a substantial 47% share. This dominant market presence is largely driven by the United States, where a significant portion of asthma treatments are developed and consumed. However, the US asthma drugs market faces unique challenges, including the impact of the Pharmacy Benefit Manager (PBM) rebate system, often referred to as the "PBM Rebate Wall." This system affects drug pricing and accessibility, creating complexities that influence market dynamics and patient access to therapies.
Compounding this environment is the introduction of the Inflation Reduction Act (IRA), set to take effect in 2026, which aims to negotiate drug prices to reduce costs for consumers. The initial list of ten drugs selected for price negotiation under the IRA predominantly targets cardiovascular and diabetes medications, such as Eliquis and Jardiance, reflecting the government's focus on high-spending drug categories.

Leading Market Participants

AbbVie Inc.
Amgen Inc.
AstraZeneca
Boehringer Ingelheim Intl. GmbH
Chiesi Farmaceutici S.p.A.
Cipla Ltd
Covis Pharma GmbH
F. Hoffmann-La Roche Ltd
GlaxoSmithKline plc
Lupin Ltd
Merck & Co., Inc.
Novartis AG
Orion Corporation
Pfizer Inc.
Regeneron Pharmaceuticals Inc.
Sanofi
Sumitomo Dainippon Pharma Co., Ltd
Takeda Pharmaceutical Co. Ltd
Teva Pharmaceutical Industries Ltd
Viatris Inc. (Mylan)
Other Prominent Players

Table of Content

Chapter 1. Executive Summary: Global Asthma Drugs Market

Chapter 2. Research Methodology & Research Framework

2.1. Research Objective
2.2. Product Overview
2.3. Market Segmentation
2.4. Qualitative Research
- 2.4.1. Primary & Secondary Sources
2.5. Quantitative Research
- 2.5.1. Primary & Secondary Sources
2.6. Breakdown of Primary Research Respondents, By Region
2.7. Assumption for Study
2.8. Market Size Estimation
2.9. Data Triangulation

Chapter 3. Global Asthma Drugs Market Overview

3.1. Industry Value Chain Analysis
- 3.1.1. Raw Material Suppliers (APIs, Excipients)
- 3.1.2. Drug Manufacturers (Innovator & Generic Companies)
- 3.1.3. Contract Manufacturing Organizations (CMOs)
- 3.1.4. Distributors & Wholesalers
- 3.1.5. Pharmacies (Retail & Hospital)
- 3.1.6. Healthcare Providers (Hospitals, Clinics)
- 3.1.7. End Users (Patients)
3.2. Industry Outlook
- 3.2.1. Rising Prevalence of Asthma Globally
- 3.2.2. Increasing Air Pollution & Environmental Triggers
- 3.2.3. Growing Adoption of Biologics & Targeted Therapies
- 3.2.4. Government Initiatives for Respiratory Disease Management
- 3.2.5. Advancements in Drug Delivery Systems (Inhalers, Nebulizers)
- 3.2.6. Increasing Healthcare Expenditure
- 3.2.7. Rising Awareness & Early Diagnosis
- 3.2.8. Expansion of Generic Drug Market
3.3. PESTLE Analysis
3.4. Porter's Five Forces Analysis
- 3.4.1. Bargaining Power of Suppliers
- 3.4.2. Bargaining Power of Buyers
- 3.4.3. Threat of Substitutes
- 3.4.4. Threat of New Entrants
- 3.4.5. Degree of Competition
3.5. Market Dynamics and Trends
- 3.5.1. Growth Drivers
  - 3.5.1.1. Rising Prevalence of Asthma and Respiratory Disorders
- 3.5.2. Restraints
- 3.5.3. Opportunity
- 3.5.4. Key Trend
3.6. Market Growth and Outlook
- 3.6.1. Market Revenue Estimates and Forecast (US$ Mn), 2020 - 2035
- 3.6.2. Price Trend Analysis, of Asthma Drugs

Chapter 4. Competition Dashboard

4.1. Market Concentration Rate
4.2. Company Market Share Analysis (Value %), 2025
4.3. Competitor Mapping & Benchmarking
4.4. Startup Ecosystem Analysis
4.5. M&A and Funding Landscape

Chapter 5. Global Asthma Drugs Market Analysis

5.1. Key Insights
5.2. Market Size and Forecast, 2020-2035 (US$ Mn)
- 5.2.1. By Mode Of Administration
  - 5.2.1.1. Injections
  - 5.2.1.2. Liquids
  - 5.2.1.3. Tablets And Capsules
  - 5.2.1.4. Inhalers
- 5.2.2. By Medication
  - 5.2.2.1. Long-Term Control Medications
  - 5.2.2.2. Quick Relief Medications
  - 5.2.2.3. Others
- 5.2.3. By Application
  - 5.2.3.1. Adults
  - 5.2.3.2. Pediatric
  - 5.2.3.3. Adolescent
- 5.2.4. By Organization Type
  - 5.2.4.1. Private
  - 5.2.4.2. Public
- 5.2.5. By Region
  - 5.2.5.1. North America
    - 5.2.5.1.1. The U.S.
    - 5.2.5.1.2. Canada
    - 5.2.5.1.3. Mexico
  - 5.2.5.2. Europe
    - 5.2.5.2.1. Western Europe
      - 5.2.5.2.1.1. The UK
      - 5.2.5.2.1.2. Germany
      - 5.2.5.2.1.3. France
      - 5.2.5.2.1.4. Italy
      - 5.2.5.2.1.5. Spain
      - 5.2.5.2.1.6. Rest of Western Europe
    - 5.2.5.2.2. Eastern Europe
      - 5.2.5.2.2.1. Poland
      - 5.2.5.2.2.2. Russia
      - 5.2.5.2.2.3. Rest of Eastern Europe
  - 5.2.5.3. Asia Pacific
    - 5.2.5.3.1. China
    - 5.2.5.3.2. India
    - 5.2.5.3.3. Japan
    - 5.2.5.3.4. South Korea
    - 5.2.5.3.5. Australia & New Zealand
    - 5.2.5.3.6. ASEAN
      - 5.2.5.3.6.1. Indonesia
      - 5.2.5.3.6.2. Malaysia
      - 5.2.5.3.6.3. Thailand
      - 5.2.5.3.6.4. Singapore
      - 5.2.5.3.6.5. Rest of ASEAN
    - 5.2.5.3.7. Rest of Asia Pacific
  - 5.2.5.4. Middle East & Africa
    - 5.2.5.4.1. UAE
    - 5.2.5.4.2. Saudi Arabia
    - 5.2.5.4.3. South Africa
    - 5.2.5.4.4. Rest of MEA
  - 5.2.5.5. South America
    - 5.2.5.5.1. Argentina
    - 5.2.5.5.2. Brazil
    - 5.2.5.5.3. Rest of South America

Chapter 6. North America Asthma Drugs Market Analysis

6.1. Market Dynamics and Trends
- 6.1.1. Growth Drivers
- 6.1.2. Restraints
- 6.1.3. Opportunity
- 6.1.4. Key Trends
6.2. Market Size and Forecast, 2020-2035 (US$ Mn)
- 6.2.1. By Mode Of Administration
- 6.2.2. By Medication
- 6.2.3. Application
- 6.2.4. Organization Type
- 6.2.5. By Country

Chapter 7. Europe Asthma Drugs Market Analysis

7.1. Market Dynamics and Trends
- 7.1.1. Growth Drivers
- 7.1.2. Restraints
- 7.1.3. Opportunity
- 7.1.4. Key Trends
7.2. Market Size and Forecast, 2020-2035 (US$ Mn)
- 7.2.1. By Mode Of Administration
- 7.2.2. By Medication
- 7.2.3. Application
- 7.2.4. Organization Type
- 7.2.5. By Country

Chapter 8. Asia Pacific Asthma Drugs Market Analysis

8.1. Market Dynamics and Trends
- 8.1.1. Growth Drivers
- 8.1.2. Restraints
- 8.1.3. Opportunity
- 8.1.4. Key Trends
8.2. Market Size and Forecast, 2020-2035 (US$ Mn)
- 8.2.1. By Mode Of Administration
- 8.2.2. By Medication
- 8.2.3. Application
- 8.2.4. Organization Type
- 8.2.5. By Country

Chapter 9. Middle East & Africa Asthma Drugs Market Analysis

9.1. Market Dynamics and Trends
- 9.1.1. Growth Drivers
- 9.1.2. Restraints
- 9.1.3. Opportunity
- 9.1.4. Key Trends
9.2. Market Size and Forecast, 2020-2035 (US$ Mn)
- 9.2.1. By Mode Of Administration
- 9.2.2. By Medication
- 9.2.3. Application
- 9.2.4. Organization Type
- 9.2.5. By Country

Chapter 10. South America Asthma Drugs Market Analysis

10.1. Market Dynamics and Trends
- 10.1.1. Growth Drivers
- 10.1.2. Restraints
- 10.1.3. Opportunity
- 10.1.4. Key Trends
10.2. Market Size and Forecast, 2020-2035 (US$ Mn)
- 10.2.1. By Mode Of Administration
- 10.2.2. By Medication
- 10.2.3. Application
- 10.2.4. Organization Type
- 10.2.5. By Country